A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Latest Information Update: 10 Nov 2020
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 01 Oct 2020 Results integrating analysis of three clinical trials (NCT02202980, NCT02613871 and NCT02738333) published in the Hepatology Research
- 24 Oct 2017 Primary endpoint (Proportion of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)) has been met, as per results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
- 24 Oct 2017 Results assessing virologic response presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.